Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
Jerini and Baxter AG Formalize Research Collaboration
 

Jerini AG, a pharmaceutical company headquartered in Berlin, announced that it is expanding its existing research collaboration with Baxter AG. The two pharmaceutical companies, which have been working on the development of a nonintravenous treatment for hemophilia patients, will develop two research programs aimed at novel approaches to creating new therapies. Their original partnership began in 2001 and was first expanded in 2004.        

 

“We are very pleased with the successful progress in our collaboration with Baxter and their decision to expand this alliance.“ said Jens Schneider-Mergener, chief executive officer at Jerini AG. “Our proprietary Peptides-to-Drugs (P2D) technology platform offers a novel and highly effective approach in the development of a new therapeutic peptide-derived injectable and oral compounds.”

 

As part of the agreement, Jerini AG will receive upfront payments and funding for each of the two new programs. It will also have the potential for milestone payments if achievement of certain discovery and clinical goals are met, along with royalties on eventual product sales.

 

Source: Jerini AG news release dated February 6, 2007